Asset
BIRTAMIMAB
PROTHENA CORPORATION PLC ORDINARY SHARES
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04973137 | phase3 | terminated | 2021-08-30 | 2025-04-02 | Prothena Biosciences Ltd. | A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis |
| NCT02613182 | phase2 | terminated | 2016-02-01 | 2018-05-01 | Prothena Biosciences Ltd. | Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis |
| NCT01707264 | phase1_2 | completed | 2013-04-01 | 2016-08-09 | Prothena Biosciences Ltd. | Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis |
| NCT03154047 | phase2 | terminated | 2017-06-14 | 2018-05-30 | Prothena Biosciences Ltd. | Study in Subjects With Light Chain (AL) Amyloidosis |
| NCT02632786 | phase2 | completed | 2016-03-01 | 2018-03-01 | Prothena Biosciences Ltd. | The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis |
FDA applications (0)
This company has no applications containing this asset.